Monitoring HIV DNA and cellular activation markers in HIV-infected humanized mice under cART

[1]  C. Rouzioux,et al.  Total HIV DNA: a global marker of HIV persistence , 2018, Retrovirology.

[2]  G. Kukolj,et al.  An advanced BLT-humanized mouse model for extended HIV-1 cure studies , 2018, AIDS.

[3]  T. Chun,et al.  In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication , 2017, PLoS pathogens.

[4]  A. Tager,et al.  Humanized mouse models of latent HIV infection. , 2017, Current opinion in virology.

[5]  H. Gendelman,et al.  A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy , 2017, Retrovirology.

[6]  Tai-sheng Li,et al.  Factors Associated with the Size of HIV DNA Reservoir , 2017, Chinese medical journal.

[7]  S. Migueles,et al.  Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size , 2016, Journal of Virology.

[8]  C. Rouzioux,et al.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications , 2016, Clinical Microbiology Reviews.

[9]  Todd M. Allen,et al.  Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo. , 2016, Journal of Infectious Diseases.

[10]  F. Lucht,et al.  Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients , 2016, Retrovirology.

[11]  D. Hazuda,et al.  In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection , 2016, Retrovirology.

[12]  Wei-jun Zhu,et al.  Analysis of HIV-1c-Specific CTL Responses with HIV-1 Reservoir Size and Forms. , 2016, Viral immunology.

[13]  H. Gendelman,et al.  HIV-1 cellular and tissue replication patterns in infected humanized mice , 2016, Scientific Reports.

[14]  M. Lichterfeld,et al.  Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth , 2016, PLoS pathogens.

[15]  F. Kashanchi,et al.  Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells. , 2015, Virology.

[16]  Nancie M Archin,et al.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.

[17]  D. Richman,et al.  During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ , 2015, EBioMedicine.

[18]  R. Siliciano,et al.  Towards an HIV-1 cure: measuring the latent reservoir. , 2015, Trends in microbiology.

[19]  Jessica L. Prince,et al.  Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression , 2015, Proceedings of the National Academy of Sciences.

[20]  J. Mellors,et al.  HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Nussenzweig,et al.  Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice , 2014, Cell.

[22]  Brendan B. Larsen,et al.  Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection , 2014, Science.

[23]  S. Hughes,et al.  Specific HIV integration sites are linked to clonal expansion and persistence of infected cells , 2014, Science.

[24]  Alan S Perelson,et al.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.

[25]  E. Rosenberg,et al.  HIV-1 persistence in CD4+ T cells with stem cell-like properties , 2014, Nature Medicine.

[26]  D. Cooper,et al.  HIV DNA Subspecies Persist in both Activated and Resting Memory CD4+ T Cells during Antiretroviral Therapy , 2014, Journal of Virology.

[27]  H. Hatano,et al.  Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. , 2013, The Journal of infectious diseases.

[28]  Jeffrey N. Martin,et al.  Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. , 2013, The Journal of infectious diseases.

[29]  D. Douek,et al.  Immune activation and HIV persistence: implications for curative approaches to HIV infection , 2013, Immunological reviews.

[30]  C. Rouzioux,et al.  Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. , 2013, The Journal of antimicrobial chemotherapy.

[31]  R. Flavell,et al.  Human hemato-lymphoid system mice: current use and future potential for medicine. , 2013, Annual review of immunology.

[32]  R. Siliciano,et al.  Redefining the viral reservoirs that prevent HIV-1 eradication. , 2012, Immunity.

[33]  R. Speck,et al.  Modeling HIV infection and therapies in humanized mice. , 2012, Swiss medical weekly.

[34]  E. Schlaepfer,et al.  Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1 , 2012, PloS one.

[35]  M. Marsden,et al.  HIV Latency in the Humanized BLT Mouse , 2011, Journal of Virology.

[36]  D. Margolis,et al.  Latent HIV-1 Infection of Resting CD4+ T Cells in the Humanized Rag2−/− γc −/− Mouse , 2011, Journal of Virology.

[37]  M. Swanson,et al.  Generation of HIV Latency in Humanized BLT Mice , 2011, Journal of Virology.

[38]  C. B. Hare,et al.  Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. , 2010, The Journal of infectious diseases.

[39]  M. Kamiyama,et al.  Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. , 2010, BioTechniques.

[40]  O. Yang,et al.  Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice , 2009, PloS one.

[41]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[42]  U. Yrlid,et al.  Steady-state migrating intestinal dendritic cells induce potent inflammatory responses in naive CD4+T cells , 2009, Mucosal Immunology.

[43]  R. Sékaly,et al.  Cellular and molecular mechanisms of memory T-cell survival , 2009, Expert review of vaccines.

[44]  R. Kaul,et al.  Immune reconstitution in the sigmoid colon after long-term HIV therapy , 2008, Mucosal Immunology.

[45]  R. Haubrich,et al.  Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. , 2008, The Journal of infectious diseases.

[46]  A. Haase,et al.  Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1 , 2006, Nature Medicine.

[47]  A. Cumano,et al.  Molecular and functional evidence for activity of murine IL-7 on human lymphocytes. , 2006, Experimental hematology.

[48]  Peter Hunt,et al.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. , 2004, Blood.

[49]  J. Flamm,et al.  Severe CD4+ T-Cell Depletion in Gut Lymphoid Tissue during Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in Restoration following Highly Active Antiretroviral Therapy , 2003, Journal of Virology.

[50]  S. Hansen,et al.  Duration of antiviral immunity after smallpox vaccination , 2003, Nature Medicine.

[51]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[52]  Anthony S. Fauci,et al.  AIDS: Re-emergence of HIV after stopping therapy , 1999, Nature.

[53]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[55]  A. Spivak,et al.  HIV-1 Eradication: Early Trials (and Tribulations). , 2016, Trends in molecular medicine.